Kardigan, Inc. (KARD)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification
Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key clinical readouts before further funding is needed. Upcoming 2027 data from all three lead programs will be pivotal in validating KARD's hypotheses and informing future capital allocation.
Kardigan, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 11,355 | $270,820 | $216,312.75 | -$54,507.25 | -20.13% |
 George Soros Soros Fund Management LLC | 15,000 | $357,750 | $288,678 | -$69,072 | -19.31% |
 Point72 Asset Management LP Point72 Asset Management LP | 12,386 | $295,406 | $250,197.2 | -$45,208.8 | -15.3% |
 David Kim Paradigm Biocapital Advisors LP | 900,000 | $21.46M | $17.14M | -$4.32M | -20.13% |
| NM Nir Messafi Deep Track Capita LLP | 600,000 | $14.31M | $11.43M | -$2.88M | -20.13% |
Kardigan, Inc. (KARD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kardigan, Inc. ever had a stock split?
Kardigan, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Tassos Gianakakos CEO | NASDAQ (NMS) Exchange | 485925101 CUSIP |
| US Country | 241 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Kardigan is an innovative clinical-stage precision therapeutics company dedicated to addressing critical unmet needs in cardiovascular disease treatment. Focused on the development of targeted therapies, the company aims to create effective medicines that tackle the root causes of specific cardiovascular conditions that currently lack approved treatments. Through its clinical-stage programs, Kardigan is poised to make significant advancements in the field of cardiovascular medicine.
Products and Services
- Danicamtiv
Danicamtiv is a promising therapeutical candidate designed to improve cardiac contractility. It targets the underlying mechanisms of heart failure with reduced ejection fraction, providing a novel approach to enhancing heart performance in patients where existing therapies may fall short.
- Ataciguat
Ataciguat is a cutting-edge investigational therapy targeting specific pathways that contribute to pulmonary hypertension. By focusing on the root causes, Ataciguat aims to deliver a more effective treatment option for patients suffering from this debilitating condition, where current approved medications do not adequately address the underlying pathology.
- Tonlamarsen
Tonlamarsen represents a novel approach in the treatment of atherosclerosis, working to address the excessive inflammatory processes that contribute to cardiovascular risk. This product aims to mitigate plaque formation in arteries, thereby reducing the risk of cardiovascular events in at-risk populations, filling a significant gap in available therapies.
